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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanBackground: Hyperglycemia is common during treatment for pediatric acute lymphoblastic
leukemia (ALL). Several risk factors have been proposed, but emergence of new evidence sug-
gests conflicting results. In view of ethnic differences in the propensity for diabetes, this study
aims to delineate the characteristics of pediatric patients at risk for hyperglycemia during
chemotherapy in Taiwan.
Methods: This retrospective study involved chart review of consecutive patients younger than
18 years with diagnosis of ALL in a medical center in Taiwan from 1997 to 2008. Hyperglycemia
was defined by random plasma glucose levels 200 mg/dL or fasting glucose levels 126 mg/dL
in at least two separate samplings. Risk factors for hyperglycemia were described with crude
and adjusted odds ratios (OR) with 95% confidence intervals (CI) in the univariate and multivar-
iate regression analysis.
Results: A total of 133 patients were included for analysis. Overall, 22 patients (16.5%) expe-
rienced hyperglycemia during ALL treatment. Most hyperglycemic episodes occurred within
the first 8 days after prednisolone use. Age older than 10 years was the most important predic-
tor of hyperglycemia (adjusted ORZ 10.88, 95% CI 2.40e49.37). Patients with fasting glucose
concentration 100 mg/dL were also 5.7-fold (95% CI 1.63e19.93) more likely to develop hy-
perglycemia, whereas the predictive significance of obesity was attenuated after adjustment.
Conclusion: Assessment of glucose concentration should be vigilant in the 1st week after pred-
nisolone use during ALL treatment. Clinicians should be alert to the patient at risk of hypergly-
cemia, particularly obese adolescents with disarranged glucose homeostasis.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.of Pediatrics, National Cheng Kung University Hospital, 138, Shengli Road, Tainan, Taiwan.
u.tw (J.-S. Chen).
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340 M.-C. Tsai et al1. IntroductionOverweight and obesity in childhood and adolescence have
been implicated in association with various adverse health
consequences.1,2 The rising prevalence of obesity among
children is an emerging problem of public health worldwide
and Taiwan is no exception.3 A particular concern for
obesity in childhood is given to the increased likelihood of
deregulation in glucose metabolism during and even after
treatment for acute lymphoblastic leukemia (ALL).4,5
Hyperglycemia is a common occurrence in pediatric
patients during induction chemotherapy of ALL.6e8 The
potential causes may include beta cell dysfunction caused
by chemotherapeutic drugs such as L-asparaginase,
increased insulin resistance and hepatic gluconeogenesis
induced by corticosteroids, or synergistic effects of these
medications, given that these pharmacological agents are
usually combined during initial induction therapy.4,5 The
spectrum of hyperglycemia can range widely from transient
isolated episodes to severe life-threatening complications
such as diabetic ketoacidosis or nonketotic hyperglycemic
hyperosmolar syndrome.9e11 Transient hyperglycemia
developed during this period largely resolves as the
chemotherapy is discontinued.12 However, affected chil-
dren may need longer hospitalization and delay in chemo-
therapy; they may experience increased infective
incidence and may even have poorer survival outcomes.13,14
Recognizable risk factors for treatment-related hypergly-
cemia have been studied among children who are charac-
terized by Down syndrome, older than 10 years of age,
obese at the start of chemotherapy, classified in the higher
risk group for ALL, and using native L-asparaginase.5e7,12,13
However, several conflicting results in more recent studies
have indicated the absence of significant associations be-
tween weight status and hyperglycemic episodes.8,14e16
Given the rising rate of obesity and overweight among
Taiwanese children, in the past 10 years, those who receive
treatment for leukemia may be at a higher risk for sec-
ondary hyperglycemia. Because ALL treatment protocol
evolves over time, the side effects of therapy should be
continually reevaluated. Few published data have referred
to the epidemiology of treatment-related hyperglycemia in
Asian pediatric patients with ALL.17 The purpose of the
current study is to evaluate the incidence and risk factors
of hyperglycemia during the treatment for leukemia among
Taiwanese children.
2. Materials and methods
This is a retrospective study involving a cohort of consec-
utive patients, age younger than 18 years, in whom ALL was
diagnosed and who were admitted to National Cheng Kung
University Hospital, Tainan, Taiwan, between January 1997
and December 2008. The hospital is a tertiary medical
center for children with pediatric cancer diseases from
Tainan and neighboring municipalities.
2.1. Variables and measures
Using the body mass index (BMI) growth chart among
normative Taiwanese children beginning at 2 years of age,we excluded patients who were younger than 2 years.18
Children with previously diagnosed diabetes mellitus (DM)
or who were treated with glucocorticoids were also
excluded. Medical records were reviewed to obtain rele-
vant clinical data, including demographic information, such
as age at diagnosis, sex, weight, height, and family history
of diabetes as well as clinical parameters, such as initial
white blood cell count (WBC), initial C-reactive protein
(CRP) level, initial fasting glucose level, immunotyping of
leukemic cells, risk classification, and outcome variables,
such as leukemic relapse, death, and infective complica-
tions. Our standard practice is to admit all patients with
fever or suspected vesicular skin lesions and to treat them
with empirical antibiotics or antiviral agents accordingly.
Infective complications were thus defined as occurrences of
aforementioned episodes at any time of the entire
chemotherapy regardless of clinical severity or identifiable
pathogens after investigation. Family history of diabetes
was defined by the presence of diabetes mellitus in pa-
tients’ first- or second-degree relatives. Hyperglycemia was
defined as at least two separate random plasma glucose
levels 200 mg/dL or fasting glucose levels 126 mg/dL
according to the published guidelines for childhood dia-
betes.19 Fasting glucose concentrations were checked
before chemotherapy and routinely as indicated during
hospitalization. Moreover, patients with hyperglycemia or
glucosuria received more intense monitoring for plasma
glucose levels. BMI was calculated by dividing weight in
kilograms by height in square meters. We determined the
weight status according to the gender and age-specific BMI
charts using the Taiwan reference data. BMI from the 5th
percentile to less than the 85th percentile was classified as
“healthy weight”; BMI from the 85th percentile to less than
the 95th percentile was classified as “overweight”; and
BMI greater than the 95th percentile was classified as
“obesity”.18,20 The 1st day of treatment was designated
when the use of steroids was started. The entire procedure
was approved by the Institutional Review Board of National
Cheng Kung University Hospital, Tainan, Taiwan.2.2. Treatment regimens
All patients were treated according to the protocols of the
Taiwan Pediatric Oncology Group (TPOG). Given that the
study period spanned from 1997 to 2008, some modifica-
tions are worthy of mention in the TPOG protocols in 2002.
Before 2002, patients in the standard-risk (SR) and high-risk
(HR) groups received the treatment regimens of TPOG-ALL-
93 SR/HR, and those with patients in the very-high-risk
(VHR) groups received the treatment regimen of TPOG-ALL-
97 VHR. After 2002, these protocols were merged as the
TPOG-ALL-2002. In brief, patients in the SR group received
a 5-week induction remission regimen that consisted of
prednisolone, vincristine, and either epirubicin or L-aspar-
aginase in the TPOG-ALL-93 SR/HR, whereas epirubicin was
only used as the third chemotherapeutic drug in the TPOG-
ALL-2002. In addition, an additional nine doses of L-aspar-
aginase were concurrently administered in the remission
induction treatment in the case of the HR patients.
Although 300 mg/m2 for SR patients and 600 mg/m2 of
etoposide for HR patients were given in the TPOG-ALL-93
Hyperglycemia During Chemotherapy 341SR/HR, this drug was no longer used in the TPOG-ALL-2002.
The other major difference in induction therapy was
prednisolone dosage, which was reduced from 60 mg/m2 in
the TPOG-ALL-93 SR/HR to 40 mg/m2 in the TPOG-ALL-
2002. After clinically complete remission was achieved,
patients further received consolidation therapy that con-
sisted of intermediate doses of methotrexate and
mercaptopurine and subsequent maintenance treatment. A
reinduction course was applied during the consolidation
phase for standard-risk patients and during the mainte-
nance phase for the HR patients. Instead, the VHR patients
received a 6-week remission induction therapy of prednis-
olone, vincristine, idarubicin, and L-asparaginase, followed
by a 4-week course of cyclophosphamide, cytarabine, and
mercaptopurine. Although drugs used in the consolidation
phase were identical to those used in the HR patients, a
reinduction course ensued after the consolidation phase.
The regimen used in the continuation phase was basically
composed of four pairs of multiple drugs with a weekly
rotation. All VHR patients received a triple intrathecal
therapy. Detailed combinations for antileukemic medica-
tions can be obtained elsewhere.212.3. Statistical analysis
We compared demographic and clinical differences be-
tween patients with and without hyperglycemia during ALL
treatment using a Student t test for continuous variables
and a Chi-square test for categorical variables with p < 0.05
considered statistically significant. The odds ratios (OR) of
probability of developing hyperglycemia in patients with
certain characteristics were described. Those predictive
parameters with statistical significance in the initial uni-
variate analysis were further entered into multivariate lo-
gistic regression analysis to adjust for potential
confounding variables. All statistical analyses were con-
ducted using software SPSS version 17.0 (SPSS Inc., Chicago,
IL, USA).3. Results
One hundred and seventy children were identified to have
ALL in the medical charts, of whom only 133 (78.2%) were
eligible for final analysis. Thirty-seven patients were
excluded due to the following reasons: age < 2 years,
against-advice discharge before induction chemotherapy,
receipt of induction therapy in other hospitals, presence of
hyperglycemia before induction chemotherapy, and mor-
tality due to infection before or during induction
chemotherapy.
Table 1 summarizes the demographic and clinical char-
acteristics of the study population. Median age at diagnosis
was 5.9 years (range 2.1e17.9 years). Of the 133 patients,
76 (57.1%) were male; 27 (20.3%) were overweight or obese;
and 13 (9.8%) had a family history of diabetes. Elevated
fasting glucose at diagnosis was noted among 23 patients
(17.3%). In terms of diagnosis and treatment, 112 patients
(84.2%) patients received a diagnosis of B-cell lineage, and
84 (63.2%) received the TPOG-ALL-2002 regimen. There
were 29 relapses (21.8%) during the time of the study, 24(82.8%) of whom were refractory to the rescue therapy and
consequently died of relapse.
Overall, hyperglycemia developed in 22 patients
(16.5%); two of these patients had diabetic ketoacidosis
and were treated with insulin. Among them, 19 hypergly-
cemic occurrences (86.4%) were noted within the first 8
days (median Z 5) after prednisolone use (Figure 1).
Another patient had a hyperglycemic episode on Day 23,
and the other two patients had hyperglycemic episodes
during the reinduction periods with dexamethasone use.
Comparing those with and without hyperglycemia during
treatment, frequency of hyperglycemic episodes differed in
regard to age, BMI status, fasting glucose status, and risk
group classification (Table 1). Immunotyping and protocols
did not differentiate the occurrence of hyperglycemia.
Patients with hyperglycemia had a lower number of infec-
tive episodes, which was 5.08 times as compared to 8.08
times in their counterparts. No obvious differences were
seen in regard to the percentage of leukemia relapse. The
chemotherapy was not changed for patients with hyper-
glycemia, as follow-up serum glucose levels gradually
normalized, and the use of insulin could be successfully
tapered for those with diabetic ketoacidosis. None of them
had persistently elevated glucose levels after discontinua-
tion of chemotherapy.
In the initial univariate analysis, hyperglycemia was
18.21 times more likely to develop in patients older than 10
years than in those younger than 10 years (Table 2).
Because patients older than 10 years should receive at least
HR chemotherapy according to the TPOG risk classification
system, we excluded SR patients from a subgroup analysis
showing that patients older than 10 years still had a
higher rate (18/39) of hyperglycemic occurrence than their
younger peers (2/44) (F Z 19.57, p < 0.001). After
adjusting for other possible covariates, age remained the
strongest predictive factor for hyperglycemia among
ALL patients (adjusted OR Z 10.88, 95% CI 2.4e49.37).
Impaired fasting glucose at the time of diagnosis was also
associated with hyperglycemia during chemotherapy (crude
OR Z 8.25, 95% CI 2.95e23.07; adjusted OR Z 5.7, 95% CI
1.63e19.93). In addition, the increase in likelihood of hy-
perglycemia among patients who were obese (crude
OR Z 4.38, 95% CI 1.35e14.2) and classified into high
groups (crude OR Z 10.76, 95% CI 2.26e51.12), compared
to the standard risk group as a reference, was diminished
after multivariate adjustment.4. Discussion
In our study, hyperglycemia was found to be a common
occurrence during chemotherapy among Taiwanese pedi-
atric patients. The prevalence was 16.5%, similar to that
found in previous pediatric research. Pui and colleagues
reported that 9.7% of patients experienced hyperglycemia
during induction therapy in the early 1980s.12 The following
surveys estimated slightly increased rates in the range of
10e20%.6e9 In order to identify the peak of hyperglycemic
occurrence, we specifically looked at the timing in rela-
tionship to phases of treatment and the use of chemo-
therapy. As the TPOG-ALL protocol described, the start of
chemotherapy is usually concomitant with the use of
Table 1 Demographic and clinical characteristics of the study population.
Variables Total Hyperglycemia
N (%) Yes, n (%) No, n (%) p
Sex
Male 76 (57.1) 11 (14.5) 65 (85.5) 0.459
Female 57 (42.9) 11 (19.3) 46 (80.7)
Age
2e9 y 93 (69.9) 4 (4.3) 89 (95.7) <0.001
10e18 y 40 (30.1) 18 (45.0) 22 (55.0)
BMI status
Normal 106 (79.7) 14 (13.2) 92 (86.8) 0.03
Overweight 12 (9.0) 2 (16.7) 10 (83.3)
Obese 15 (11.3) 6 (40.0) 9 (60.0)
Family history of diabetes
No 120 (90.2) 19 (15.8) 101 (84.2) 0.50
Yes 13 (9.8) 3 (23.1) 10 (76.9)
Fasting glucose
<100 mg/dL 110 (82.7) 11 (10.0) 99 (90.0) <0.001
100 mg/dL 23 (17.3) 11 (47.8) 12 (52.2)
White blood cells/mm
<50  103 94 (70.7) 17 (18.1) 77 (81.9) 0.46
50  103 39 (29.3) 5 (12.8) 34 (87.2)
C-reactive protein*
<20 mg/dL 73 (54.9) 14 (19.2) 59 (80.8) 0.24
20 mg/dL 58 (43.6) 7 (12.1) 51 (87.9)
Immunotype
B-cell 112 (84.2) 19 (17.0) 93 (83.0) 0.76
T-cell 21 (15.8) 3 (14.3) 18 (85.7)
Risk group
Standard risk 50 (37.6) 2 (4.0) 48 (96.0) 0.002
High risk 42 (31.6) 13 (31.0) 29 (69.0)
Very high risk 41 (30.8) 7 (17.1) 34 (82.9)
Treatment protocol
TPOG-ALL-93/97 49 (36.8) 4 (8.2) 45 (91.8) 0.05
TPOG-ALL-2002 84 (63.2) 18 (21.4) 66 (78.6)
Leukemia relapse
Yes 29 (21.8) 5 (17.2) 24 (82.8) 0.91
No 104 (78.2) 17 (16.3) 87 (83.7)
Mean number of infective
episodes per person (SD)
7.58 ( 6.49) 5.09 ( 4.93) 8.08 ( 6.66) 0.52
ALL Z acute lymphoblastic leukemia; BMI Z body mass index; SD Z standard deviation; TPOG Z Taiwan Pediatric Oncology Group.
* There were two missing values excluded from the denominator.
Figure 1 Number and accumulation percentage of hyperglycemia after prednisolone use.
342 M.-C. Tsai et al
Table 2 Risk factors of hyperglycemia during chemotherapy for pediatric acute lymphoblastic leukemia.*
Univariate Multivariate
Crude OR (95% CI) Adjusted OR (95% CI)
Age (y)
2e9 1.00 1.00
10e18 18.21x (5.60e59.22) 10.88z (2.40e49.37)
BMI status
Normal 1.00 1.00
Overweight 1.31 (0.26e6.63) 1.62 (0.21e12.50)
Obesity 4.38y (1.35e14.20) 4.00 (0.79e20.17)
Fasting glucose
<100 mg/dL 1.00 1.00
100 mg/dL 8.25x (2.95e23.07) 5.70z (1.63e19.93)
Risk group
Standard risk 1.00 1.00
High risk 10.76z (2.26e51.12) 1.89 (0.25e14.30)




CI Z confidence interval; OR Z odds ratio.
* Adjustment was made for all possible contributing factors in the multivariate logistic regression analysis using occurrence of hy-
perglycemia as the dependent variable.
Hyperglycemia During Chemotherapy 343steroids.21 However, this protocol is sometimes subject to
changes in practice, so chemotherapeutic agents may
actually begin several days after administration of steroids.
We found that hyperglycemia occurred most often within
the 1st week after prednisolone use. The second peak of
occurrence was within the stretch of the reinduction phase,
which is thought to be associated with dexamethasone use.
Interestingly, no patients with hyperglycemia during the
induction phase developed another hyperglycemic episode
in the following reinduction phases. This finding may sup-
port Sonabend et al’s13 research showing a higher rate of
hyperglycemia in patients receiving prednisolone than
counterparts receiving dexamethasone. Our retrospective
study was not able to evaluate the aforementioned obser-
vation with head-to-head comparison. More clinical obser-
vations or pooled data may be needed to compare
hyperglycemic effects of different corticosteroids in use.
Previous studies have been supportive of a positive associ-
ation between the occurrence of hyperglycemia and the
use of chemotherapeutic agents, particularly L-aspar-
aginase.6,12 Corticosteroids are commonly coadministered
with L-asparaginase in chemotherapy for ALL, thus making
it difficult to attribute cause of hyperglycemia to any single
medication use. None of the hyperglycemic patients had
concurrent hyperlipidemia or pancreatitis, which is even
rarer (6e8%) in incidence and may cause permanent
DM.22,23 Our findings would suggest that steroids are the
main culprit leading to hyperglycemia by interacting with
pubertal hormones, adiposity, and other medications used
in the treatment. Meanwhile, leukemic cells themselves
may also alter the metabolism of adipose cytokines and
induce systemic inflammatory processes.24 Together, these
predisposing factors may further result in redistribution of
adipose tissue and derangement of glucose regulation.25,26
Age was shown to be the most important contributor to
hyperglycemia during ALL treatment in the analysis. Nearly40% of patients older than 10 years developed hyperglyce-
mia as opposed to only 3.2% of those younger than 10 years.
Such a striking increase in the prevalence of hyperglycemia
during adolescence has also been noted in previous studies
conducted in USA and Canada.6e9,12 This may reflect rising
insulin resistance under the influence of sex hormones
along with pubertal progression.27 The magnitude of insulin
resistance can interact with and be further exaggerated by
adiposity gained during the critical period of physical
transition. As predicted, BMI status was also significantly
related to the occurrence of hyperglycemia in the univari-
ate analysis. Obesity is the major and most common cause
of insulin resistance in the pediatric age group because
excess adiposity, especially visceral adiposity, is considered
to be a major risk factor for development of impaired
glucose metabolism and metabolic syndrome in youth.28,29
Extending previous knowledge and measuring the effect
of glucose metabolism among pediatric ALL patients, we
added fasting glucose in the analysis model. Patients with
elevated fasting glucose were found to be approximately
five times more likely to have hyperglycemia during
chemotherapy even after multivariate adjustment. In our
analysis, we hypothesized that fasting glucose concentra-
tion could possibly mediate the effect of obesity on sub-
sequent occurrences of hyperglycemia. Fasting glucose
level is an essential laboratory marker of glucose toler-
ance.30 Impaired glucose tolerance at the time of diagnosis
may put affected patients at a greater risk for diabetes,
and thus meticulous monitoring of glucose levels in subse-
quent management is warranted.31 Direct measurement of
insulin secretion was, however, not conducted in this
retrospective study. Although the magnitude of insulin
resistance could be assessed more accurately by an oral
glucose tolerance test, its correlation with occurrence of
hyperglycemia during treatment has not been verified and
requires further investigation.
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perglycemia seemed to have more infective episodes in our
cohort. One possible reason may be that older patients are
likely to develop hyperglycemia due to insulin resistance
but are usually more immune to common infective diseases.
In addition, younger patients are more likely to have con-
tact with sick children in school and to exhibit severe
clinical presentations that require hospitalization because
of immune immaturity. As such, the relationship between
infective outcomes and occurrences of hyperglycemia
during leukemic treatment could be largely confounded by
patient age. Also worthy of attention is that our operative
symptom-based definition of infection, which is symptom-
based, may not truly reflect the cause and severity of
infective episodes. Fever inherent to leukemia itself is
sometimes indistinguishable from infection without an
identifiable pathogen. Interpretation of the difference in
the number of infections between patients with and
without hyperglycemia should be made with due caution. A
larger sample size with age-matched comparison is needed
to further explore the aforementioned relationship.
The current retrospective study has some limitations
that need be addressed along with its findings. First, the
laboratory data were retrieved from medical charts.
Although all patients received regular morning glucose as-
sessments at least twice per week in the routine clinical
care of induction chemotherapy, follow-up blood samplings
for glucose concentration were only assigned on the basis of
clinical symptoms and signs of hyperglycemia rather than at
protocol-based time points. Exact time of onset may have
therefore not been accurately recorded. Second, previous
studies have involved postprandial glucose measurements
in the diagnosis of hyperglycemia. We did not monitor
postprandial glucose levels on a regular basis. As a result,
asymptomatic postprandial hyperglycemic events were
likely to be underreported in our cohort. A prospective
standardized protocol with uniform time points at the
measurement of serum glucose concentration would be
needed to evaluate the evolution in glucose metabolism
during chemotherapy. In addition, variations in clinical care
exist among different hospitals and may alter the clinical
outcomes of hyperglycemia. A larger registry involving
multicenter pediatric patients with ALL may provide more
solid evidence of the occurrence of hyperglycemia and
associated clinical effects in the Taiwanese population.
In conclusion, our data have provided an overview of
glycemic complications among patients treated with TPOG
protocols. Assessment of glucose concentration should be
performed with vigilance in pediatric patients receiving
chemotherapy for leukemia especially within the 1st week
after prednisolone use, notably in obese adolescents. The
strength of our study is it showed that fasting glucose could
add predictive value to subsequent occurrence of hyper-
glycemia during chemotherapy. Based on this finding, we
could better stratify ALL patients against risks for hyper-
glycemia and take preemptive actions to control glucose
levels. The presence of hyperglycemia is usually transient
with gradual resolution and thusmay not necessarily warrant
change of the treatment protocol. Although no differences
in terms of leukemia relapse and infection occurrence were
observed between patientswith andwithout hyperglycemia,
medication-induced diabetes during ALL therapy wasrecently shown to predict the development of metabolic
derangements in this population in the long term.32 The
implications of these findings are twofold. With advance-
ment of antileukemic therapy, continuous care and follow-
up of metabolic consequences are recommended for survi-
vors. Second, identifying the presence of factors predicting
hyperglycemia (older age, abnormal glucose level at base-
line, and possibly abnormal BMI) may lead to the early
implementation of lifestyle changes; for example; during
the induction-remission therapy. Whether these early life-
style modifications could benefit the patients at risk for
transient or long-term impaired glucose homeostasis will
require further investigation.
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